Compare
Vsee Health, Inc. vs Agape ATP Corp vs Omada Health, Inc. vs GeneDx Holdings Corp.
| Latest fiscal year | Vsee Health, Inc. VSEE | Agape ATP Corp ATPC | Omada Health, Inc. OMDA | GeneDx Holdings Corp. WGS |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $14.62M | $1.52M | $260.21M | $427.54M |
| Revenue growth (YoY) | +40.3% | +15.2% | +53.2% | +40.0% |
| Gross margin | 50.3% | 55.0% | 65.7% | 69.7% |
| Operating margin | -65.6% | -213.7% | -4.6% | -3.1% |
| Net margin | -100.6% | -149.6% | -4.9% | -4.9% |
| Net income | -$14.71M | -$2.28M | -$12.78M | -$21.02M |
| EPS (Diluted) | -$0.73 | -$2.85 | -$0.35 | -$0.73 |
| Operating cash flow | -$3.45M | -$2.41M | $18.25M | $33.28M |
| Free cash flow | -$3.48M | n/a | $16.93M | $14.26M |
| Cash & equivalents | $5.27M | $140.1K | $222.04M | $105.00M |
| Total assets | $22.41M | $24.59M | $305.41M | $523.71M |
| Total liabilities | $16.96M | $2.17M | $75.73M | $215.53M |
| Shareholders' equity | $5.45M | $22.46M | $229.68M | $308.18M |
| Return on year-end equity | -269.8% | -10.2% | -5.6% | -6.8% |
| Shares outstanding | 33.19M | 1.00M | 58.43M | 29.25M |
Revenue, most recent five fiscal years
| Fiscal year | Vsee Health, Inc. | Agape ATP Corp | Omada Health, Inc. | GeneDx Holdings Corp. |
|---|---|---|---|---|
| Latest | $14.62M Ended 2025-12-31 | $1.52M Ended 2025-12-31 | $260.21M Ended 2025-12-31 | $427.54M Ended 2025-12-31 |
| 1 year earlier | $10.42M Ended 2024-12-31 | $1.32M Ended 2024-12-31 | $169.80M Ended 2024-12-31 | $305.45M Ended 2024-12-31 |
| 2 years earlier | $5.77M Ended 2023-12-31 | $1.43M Ended 2023-12-31 | $122.78M Ended 2023-12-31 | $202.57M Ended 2023-12-31 |
| 3 years earlier | n/a | $1.86M Ended 2022-12-31 | n/a | $234.69M Ended 2022-12-31 |
| 4 years earlier | n/a | $1.02M Ended 2021-12-31 | n/a | $212.19M Ended 2021-12-31 |